Floatz logo

Brivaracetam

Partial Seizures With or Without Secondary Generalization

Overseas Pharmaceuticals, Ltd.Small moleculePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Partial Seizures With or Without Secondary Generalization cohort.

Asset / SponsorPhaseRating
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A
Topamax
Mario Negri Institute for Pharmacological Research
Phase 4A
Oxcarbamezapine
Mario Negri Institute for Pharmacological Research
Phase 4A

View all 50 →

Same molecule, other indications

Brivaracetam is also rated in:

epilepsyDormant
BB
Indicative ·
70 / 100
View asset →
spinal cord injuryDormant
BB
Indicative ·
68 / 100
View asset →
Unverricht-Lundborg syndromeDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →